Cargando…
Real-World Use of Immunotherapy for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality worldwide and accounts for 90% of all primary liver cancers. Chronic inflammation is the hallmark across most prevalent etiologies among which HBV is the leading cause worldwide (33%), followed by alcohol (30%)...
Autores principales: | Sara, Amir, Ruff, Samantha M, Noonan, Anne M, Pawlik, Timothy M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455985/ https://www.ncbi.nlm.nih.gov/pubmed/37637511 http://dx.doi.org/10.2147/POR.S397972 |
Ejemplares similares
-
Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress
por: Shannon, Alexander H, et al.
Publicado: (2022) -
Advances in Targeted Immunotherapy for Hepatobiliary Cancers
por: Ruff, Samantha M., et al.
Publicado: (2022) -
Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Ruff, Samantha M., et al.
Publicado: (2023) -
Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma
por: Akateh, Clifford, et al.
Publicado: (2019) -
Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances
por: Rallis, Kathrine S, et al.
Publicado: (2022)